For decades, Alzheimer's research has focused on examining amyloid plaques in the brain and prescribing antibody therapeutics that remove the plaques to slow cognitive decline in patients.
After a series of setbacks for dalzanemdor, some analysts now expect that Sage won’t reach profitability for awhile — and only if its cost structure undergoes significant changes.